SOLID TUMORS, KRAS MUTATION; SOS1

Clinical trials for SOLID TUMORS, KRAS MUTATION; SOS1 explained in plain language.

Never miss a new study

Get alerted when new SOLID TUMORS, KRAS MUTATION; SOS1 trials appear

Sign up with your email to follow new studies for SOLID TUMORS, KRAS MUTATION; SOS1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

First test of new drug targeting a key cancer driver

Disease control Ongoing

This is an early safety study for adults with advanced solid tumors that have a specific genetic change called a KRAS mutation, which makes cancer grow faster. The main goals are to find the highest safe dose of a new drug, BI 1701963, and to see if it can shrink tumors when give…

Matched conditions: SOLID TUMORS, KRAS MUTATION; SOS1

Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control

Last updated Apr 03, 2026 14:41 UTC

SOLID TUMORS, KRAS MUTATION; SOS1

Get alerted when new SOLID TUMORS, KRAS MUTATION; SOS1 trials appear

First test of new drug targeting a key cancer driver